Dysregulation of the expression of the nuclear transporter has been used as the tool for the prognosis of breast cancer, brain cancer, gastric cancer, prostate cancer, ovarian cancer, bladder cancer, liver cancer, lung cancer, oesophageal cancer and melanoma [66]. Here, RPAIN is linked to breast carcinoma.